Sells MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy and develops muscle-directed medicines for cardiovascular and neuromuscular diseases.
10-K for FY2025, filed Feb 26, 2026
Most revenue comes from partners’ upfront license fees, milestone payments tied to development, regulatory or commercial goals, and royalties on licensed-product sales; partners also reimburse research and development costs.
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$88M
10-K for FY2025, filed Feb 26, 2026
$88M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License and Milestone Revenues
Licensed
10-K for FY2025, filed Feb 26, 2026 |
90%
FY2022: 1.1%
|
License and Milestone Revenues, FY2025
$79.4M Sources
|
Licensed |
|
Collaboration Revenues
|
9.9%
FY2022: 7.0%
|
Collaboration Revenues, FY2025
$8.7M Sources
|
Cytokinetics targets cardiologists and disease-specific centers with its U.S. sales team; it has licensing arrangements with Sanofi in China and Bayer in Japan.
10-K for FY2025, filed Feb 26, 2026
No. It lost $785M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$190.1MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
Growing. Revenue grew 25% in 4 years, from $70.4M in FY2021 to $88M in FY2025, about 6% a year.
From research to sales
Cytokinetics has moved from developing investigational medicines toward selling MYQORZO as its first approved medicine, while continuing drug development.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026OverviewView ↗
Broader research approaches
Earlier research centered on small molecules that modulate muscle contractility; the latest report adds targeted protein degraders, oligonucleotides and tissue-targeting approaches.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026Our long-standing interest in the cytoskeleton has led us to focus our research and development activities on the biology of muscle…View ↗
After expanding our discovery platform to include muscle mechanics, muscle metabolism, and muscle health and regeneration, we are seeking…View ↗
Competes with Bristol Myers Squibb, Edgewise Therapeutics, Lexicon, Tenaya, Braveheart Bio (Hengrui), Novartis, Merck &, Bayer, AstraZeneca, and Kardigan
10-K for FY2025, filed Feb 26, 2026MYQORZO competes with Camzyos® (mavacamten), a cardiac myosin inhibitor marketed by Bristol Myers Squibb, as a therapy for oHCM, along with…View ↗
Loading...